Patents by Inventor Franz-Josef OBERMAIR

Franz-Josef OBERMAIR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11939572
    Abstract: The invention relates to a chimeric antigen-receptor polypeptide heterodimer comprising two polypeptides, wherein the first contains an extracellular part of the major histocompatibility complex I alpha chain and the second contains a 32-microglobulin domain, or the first contains an extracellular part of the major histocompatibility complex II alpha chain and the second contains a major histocompatibility complex II beta chain. One of the polypeptides further contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor alpha chain and the other one contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor beta chain, and additionally an antigen-peptide covalently linked to said extracellular MHC domain. The invention further relates to a method for the identification of a TCR recognizable peptide sequence making use of the heterodimer of the invention.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 26, 2024
    Assignee: ETH Zürich
    Inventors: Jan Kisielow, Franz-Josef Obermair, Manfred Kopf
  • Publication number: 20220033460
    Abstract: Approaches for identifying T cell epitopes from SARS-CoV-2 are provided, along with the use of such T cell epitopes diagnostically and therapeutically. Compositions including T cell epitope vaccines and T cell epitope-display reagents are provided. Methods for identifying SARS-CoV-2 T cell epitopes, methods of identifying reactive T cells and methods of using epitopes and T cells for diagnostic purposes, such as identifying particular patient subpopulations are provided. Treatment methods, including administration of T cell epitope vaccines prophylactically and administration of activated T cells therapeutically are also provided.
    Type: Application
    Filed: August 9, 2021
    Publication date: February 3, 2022
    Inventors: Daniel Pregibon, Joshua Francis, Del Leistritz-Edwards, William Dunn, Violeta Rayon Estrada, Gang Liu, Jan Kisielow, Franz-Josef Obermair
  • Publication number: 20210324037
    Abstract: The present invention relates to a method for simultaneous detection and enrichment of antigen-specific T cells and of the peptides specifically recognized by their T cell receptors (TCRs). The method also allows identification of T cell-specific antigens for in vivo and/or in vitro interventions including vaccination, induction of immunological tolerance, blocking of TCRs and MHC-mediated toxin delivery, for immunogenicity testing and other in vitro T-cell reactivity tests. The present invention also relates to the chimeric molecules used in said methods.
    Type: Application
    Filed: October 18, 2019
    Publication date: October 21, 2021
    Inventors: Jan KISIELOW, Franz Josef OBERMAIR, Manfred KOPF
  • Publication number: 20210132065
    Abstract: The present invention relates to a method for identifying candidate peptides presented by major histocompatibility complex (MHC) for vaccination, induction of immunological tolerance, blocking of TCRs, MHC-mediated toxin delivery and redirecting T cells with CARs, for immunogenicity testing and other in vitro T-cell reactivity tests. The invention further relates to a method for determining the MHC binding affinity of candidate peptides.
    Type: Application
    Filed: April 12, 2019
    Publication date: May 6, 2021
    Inventors: Jan KISIELOW, Franz Josef OBERMAIR, Manfred KOPF
  • Publication number: 20210123042
    Abstract: The invention relates to a chimeric antigen-receptor polypeptide heterodimer comprising two polypeptides, wherein the first contains an extracellular part of the major histocompatibility complex I alpha chain and the second contains a 32-microglobulin domain, or the first contains an extracellular part of the major histocompatibility complex II alpha chain and the second contains a major histocompatibility complex II beta chain. One of the polypeptides further contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor alpha chain and the other one contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor beta chain, and additionally an antigen-peptide covalently linked to said extracellular MHC domain. The invention further relates to a method for the identification of a TCR recognizable peptide sequence making use of the heterodimer of the invention.
    Type: Application
    Filed: November 13, 2020
    Publication date: April 29, 2021
    Inventors: Jan KISIELOW, Franz-Josef OBERMAIR, Manfred KOPF
  • Patent number: 10865408
    Abstract: The invention relates to a chimeric antigen-receptor polypeptide heterodimer comprising two polypeptides, wherein the first contains an extracellular part of the major histocompatibility complex I alpha chain and the second contains a 32-microglobulin domain, or the first contains an extracellular part of the major histocompatibility complex II alpha chain and the second contains a major histocompatibility complex II beta chain. One of the polypeptides further contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor alpha chain and the other one contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor beta chain, and additionally an antigen-peptide covalently linked to said extracellular MHC domain. The invention further relates to a method for the identification of a TCR recognizable peptide sequence making use of the heterodimer of the invention.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 15, 2020
    Assignee: ETH Zurich
    Inventors: Jan Kisielow, Franz-Josef Obermair, Manfred Kopf
  • Publication number: 20190345485
    Abstract: The invention relates to a chimeric antigen-receptor polypeptide heterodimer comprising two polypeptides, wherein the first contains an extracellular part of the major histocompatibility complex I alpha chain and the second contains a 32-microglobulin domain, or the first contains an extracellular part of the major histocompatibility complex II alpha chain and the second contains a major histocompatibility complex II beta chain. One of the polypeptides further contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor alpha chain and the other one contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor beta chain, and additionally an antigen-peptide covalently linked to said extracellular MHC domain. The invention further relates to a method for the identification of a TCR recognizable peptide sequence making use of the heterodimer of the invention.
    Type: Application
    Filed: December 16, 2015
    Publication date: November 14, 2019
    Applicant: ETH Zurich
    Inventors: Jan KISIELOW, Franz-Josef OBERMAIR, Manfred KOPF